TKT and pancreatic ductal adenocarcinoma: MiR-3663-5p can directly target TKT to diminish the nucleotide synthesis of the PPP pathway, thereby increasing gemcitabine sensitivity, which may be a supplement to chemotherapy advantages in pancreatic ductal adenocarcinoma [44].